Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Daiichi Sankyo Co Ltd Ord — FY2023 Earnings Presentation
67 slides from Daiichi Sankyo's earnings presentation, Apr 25, 2024
Slide 1: FY2023 Financial Results Presentation
FY2023 Financial Results Presentation DAIICHI SANKYO CO., LTD. Hiroyuki Okuzawa Representative Director, President & COO April 25, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda 1 FY2023 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2024 Forecast 6 Appendix 3
Slide 4: Overview of FY2023 Results
Overview of FY2023 Results (Bn JPY) FY2022 FY2023 YoY Results Results Revenue 1,278.5 1,601.7 +25.3% 323.2 Cost of sales *1 349.1 414.8 65.7 SG&A expenses *1 470.1 627.3 157.2 DXd ADC profit share *2 90.8 170.6 79.8 Other SG&A expenses 379.3 456.8 77.5 R&D expenses *1 336.7 364.3 27.6 Core operating
Slide 5: Revenue
Revenue Increased by 323.2 Bn JPY (Increased by 256.4 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2022 Results FY2022 Results 1,278.5 Japan Business Unit Inavir +15.0 Japan Business Enhertu +12.2 Japan Business0.0 (incl. Innovative Pharmaceuticals, 57.6 Generic, Vaccines,
Slide 6: Core Operating Profit
Core Operating Profit Increased by 72.7 Bn JPY (Increased by 62.1 Bn JPY excl. forex impact) (Bn JPY) Revenue +323.2 incl. forex impact of +66.8 FY2022 Results FY2022 Results 122.6 Cost of Sales +53.1 Revenue Increase in cost of sales due to the revenue increase Revenue 323.2 SG&A Expenses +131.0 Co
Slide 7: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Increased by 91.5 Bn JPY (Bn JPY) Temporary Income/Expenses +18.4 (Profit Increased) FY2022 FY2023 YoY Results Results Temporary Income 21.9*1 27.3*2 +5.4 FY2022 Results FY2022 Results 109.2 Temporary Expenses 23.9*3 10.9*4 -13.0 Core *1 Gains related to
Slide 8: Revenue: Business Units (incl. Forex Impact)
Revenue: Business Units (incl. Forex Impact) (Bn JPY) FY2022 FY2023 YoY Results Results Japan Business 457.9 518.9 +61.0 Daiichi Sankyo Healthcare 70.3 76.0 +5.6 Oncolgy Business 185.4 334.6 +149.2 Enhertu 181.6 327.4 +145.8 Turalio 3.8 5.3 +1.5 American Regent 187.4 203.4 +16.1 Injectafer 54.0 50.1
Slide 9: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2022 FY2023 YoY Results Results Lixiana anticoagulant 105.1 115.6 +10.4 treatment for osteoporosis/ inhibitor of the progression of Pralia bone erosion associated with rheumatoid arthritis 40.2 42.8 +2.6 Tarlige pain treatment 38.5 45.7 +7.2 Vimpat anti-ep
Slide 10: Agenda: Business Update
Agenda 1 FY2023 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2024 Forecast 6 Appendix 10
Slide 11: Progress towards Maximize 3ADCs
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” Progress towards “Create shared value with stakeholders” 11
Slide 12: ENHERTU Revenue
ENHERTU® Revenue (Bn JPY) <Reference> FY2023 Results FY2024 Forecast Total YoY YoY Consideration Product Sales 395.9 188.4 508.4 112.4 - Japan 23.9 12.2 25.7 1.8 - US 225.5 81.0 266.6 41.1 - Europe 101.9 64.8 152.1 50.2 - ASCA 44.6 30.4 64.0 19.4 - 10.2 * 1 10.1 * 1 Upfront payment 0.3 0.1 149.0 12.
Slide 13: ENHERTU Performance in Each Region (US, EU)
ENHERTU® Performance in Each Region (US, EU) Global product sales: FY2023 results 395.9 Bn JPY（YoY +188.4 Bn JPY）FY2024 forecast 508.4 Bn JPY（YoY +112.4 Bn JPY） US ◆ Product sales: FY2023 results 225.5 Bn JPY (1,560 Mn USD) FY2024 forecast 266.6 Bn JPY (1,839 Mn USD) ◆ Indication: HER2+ mBC 2L+, HER
Slide 14: ENHERTU Performance in Each Region (Japan, ASCA)
ENHERTU® Performance in Each Region (Japan, ASCA) Global product sales: FY2023 results 395.9 Bn JPY（YoY +188.4 Bn JPY）FY2024 forecast 508.4 Bn JPY（YoY +112.4 Bn JPY） Japan ◆ Product sales: FY2023 results 23.9 Bn JPY FY2024 forecast 25.7 Bn JPY ◆ Indication: HER2+ mBC 2L+, HER2 low mBC (post-chemo),
Slide 15: Strategic Collaboration with Merck & Co., Inc., Rahway, NJ, USA
Strategic Collaboration with Merck & Co., Inc., Rahway, NJ, USA ◆ October 2023: Decide co-development and co-commercialization of HER3-DXd, I-DXd, DS-6000 ➢ Maximize the value of 3 products by accelerating and expanding development ➢ Allocate resource rapidly with flexibility to new growth drivers f
Slide 16: Profit growth for current business and products
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” Progress towards “Create shared value with stakeholders” 16
Slide 17: LIXIANA: Growth in Each Country/Region
LIXIANAⓇ: Growth in Each Country/Region Volume Global revenue FY2023 results: 287.7 Bn JPY (YoY +43.8 Bn JPY) 50% 45% 45.1% Japan 40% 36.9% S. Korea 35% 30% 27.8% Taiwan 26.7% Belgium 25% 26.1% UK 23.6% Italy 20% 23.0% Spain 15% 17.8% Germany 10% 4.0% China 5% 3.6% Brazil 0% 0.04% USA Copyright © 20
Slide 18: LIXIANA: Growth in Japan
LIXIANAⓇ: Growth in Japan Sales ◆ No.1 sales share (FY2023 Q4: 47.2%) ◆ Revenue FY2023 results: 115.6 Bn JPY (YoY +10.4 Bn JPY) （%） Decrease in sales share due to 50 drug price revision (special expansion re-pricing) （47.2%） 40 30 20 LIXIANAⓇ Product A 10 Product B Product C 0 Copyright © 2024 IQVIA
Slide 19: Other Initiatives in Japan
Other Initiatives in Japan Enhance product portfolio ◆ VANFLYTAⓇ Anti-Cancer Agent / FLT3 Inhibitor ➢ Approved for acute myeloid leukemia (AML) 1L therapy in May 2023 Label updated from "relapsed/refractory FLT-ITD positive AML" to "FLT3-ITD positive AML" ◆ TARLIGEⓇ Orally Disintegrating Tablet ◆ DA
Slide 20: Other Regional Initiatives
Other Regional Initiatives US・EU ◆ AbraxaneⓇ (paclitaxel) generic Anti-Cancer Agent Launched (US: May 2023) ◆ VANFLYTAⓇ Anti-Cancer Agent / FLT3 inhibitor for acute myeloid leukemia (AML) 1L therapy Launched (US: Aug. 2023, EU: Feb. 2024) ◆ NilemdoⓇ / NustendiⓇ Updates ➢ Jan. 2024 DSE and Esperion T
Slide 21: Create shared value with stakeholders
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” Progress towards “Create shared value with stakeholders” 21
Slide 22: FY2023 Annual Dividend Forecast
FY2023 Annual Dividend Forecast Increase FY2023 annual dividend forecast per share to 50 JPY due to strong performance of ENHERTU® and others, and upfront payment related to strategic collaboration with MRK*1 (by 20 JPY compared to FY2022) Annual Dividend per share ➢ Forecast as of April 2023 As of
Slide 23: Agenda: R&D Update
Agenda 1 FY2023 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2024 Forecast 6 Appendix 23
Slide 24: FY2023 R&D major achievements
FY2023 R&D major achievements Realizing the strategic pillars of 5-Year Business Plan “Maximize 3ADC” and “Identify and build pillars for further growth” ENHERTU® ◼ Expanded ENHERTU® eligible target patients with tumor agnostic indication for HER2 positive solid tumors Dato-DXd ◼ BLA filings were ac
Slide 25: ASCO 2024 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2024 News Flow 25
Slide 26: ENHERTU DESTINY-PanTumor02 study
ENHERTU® DESTINY-PanTumor02 study FDA approved ENHERTU® as the first tumor agnostic HER2 directed therapy in unresectable or metastatic HER2 positive (IHC 3+) solid tumors in Apr 2024* Objective response and duration of response (ESMO 2023) OS by HER2 status (ESMO 2023) Data cut off: Jun 8th, 2023 ◼
Slide 27: Expanding treatment opportunities beyond Japan, US and EU
Expanding treatment opportunities beyond ENHERTU® Japan, US and EU Indication expansion in China has been progressing HER2 low BC* (post chemo) ◼ Approved in China in Jul 2023, based on DESTINY-Breast04 study data HER2 positive GC 3L+ ◼ Filing accepted in China in Dec 2023, based on DESTINY-Gastric0
Slide 28: Dato-DXd Progress in FY2023: NSCLC
Dato-DXd Progress in FY2023: NSCLC TROPION-Lung01 Filing accepted for nonsquamous NSCLC 2L+ in US (Feb 2024) and EU (Mar 2024), based on the data from TROPION-Lung01 study PFS in nonsquamous NSCLC (ESMO 2023) ◼ Dato-DXd median PFS: 5.6 months ◼ Docetaxel median PFS: 3.7 months ◼ PFS HR for nonsquamo
Slide 29: Dato-DXd TROPION-Lung10 study
Dato-DXd TROPION-Lung10 study New Ph3 combination study of Dato-DXd and Rilvegostomig* for 1L locally-advanced or metastatic nonsquamous NSCLC TROPION-Lung10 study design Dato-DXd 6mg/kg q3w Key Eligibility + Rilvegostomig q3w • Stage IIIB-IV nonsquamous NSCLC • No prior treatment for advanced/ R Ri
Slide 30: Dato-DXd TROPION-Lung14 study
Dato-DXd TROPION-Lung14 study Started a new Ph3 study for 1L EGFR mutated, locally advanced or metastatic nonsquamous NSCLC in Apr 2024 TROPION-Lung14 study design Key Eligibility Osimertinib 80mg QD + • EGFR mutation (Ex19Del or Dato-DXd 6mg/kg x4 q3w L858R) R • Locally advanced/metastatic 1:1 nons
Slide 31: Dato-DXd Progress in FY2023: breast cancer
Dato-DXd Progress in FY2023: breast cancer TROPION-Breast01 Filing accepted in US, EU, China and Japan for the treatment of HR+/HER2 low or negative BC, based on the data from TROPION-Breast01 study TROPION-Breast01 in BC development map TROPION-Breast01 PFS (ESMO 2023) Data cutoff: Jul 2023 ◼ Media
Slide 32: HER3-DXd Progress in FY2023
HER3-DXd Progress in FY2023 To be the first HER3-targeted drug Based on HERTHENA-Lung01 study data, filing accepted with priority review in US for EGFR-mutated NSCLC after TKI and platinum-based chemotherapy Started a new study for expanding indications (HERTHENA-PanTumor01 study) HER3-DXd developme
Slide 33: DXd ADCs Combination studies with internal asset
DXd ADCs Combination studies with internal asset Valemetostat combination with DXd ADCs Dose escalation Dose expansion Valemetostat + ENHERTU® Key Eligibility HER2+ GC or GEJ adenocarcinoma Signal generation 2L+ • Unresectable or metastatic diseases Valemetostat + Dato-DXd • Eligible for treatment w
Slide 34: ASCO 2024 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2024 News Flow 34
Slide 35: I-DXd Progress in FY2023
I-DXd Progress in FY2023 Durable efficacy and manageable safety profile were observed in multiple tumor types and a new Ph3 study in SCLC will start Efficacy analysis in selected tumor types (ESMO 2023) SCLC Dose level ESCC Dose level mCRPC Dose level squamous NSCLC Dose level ◼ cORR: 30.8% (4/13) (
Slide 36: I-DXd IDeate-Lung03 study
I-DXd IDeate-Lung03 study Plan to start combination study in 1L in FY2024 H1 to maximize the value of I-DXd in SCLC IDeate-Lung03 study design (N=149) Cohort 1 Part A: Safety Run-in Part B:Dose Optimization Part A: Maintenance Only Maintenance Maintenance Induction Arm 1: I-DXd 8 mg/kg Patients who
Slide 37: I-DXd Ph2 study targeting multiple solid tumors
I-DXd Ph2 study targeting multiple solid tumors Plan to start a new signal seeking Ph2 study in multiple cancers to investigate further possibility of I-DXd Study Design Endometrial cancer SCCHN Population • Recurrent or Metastatic solid PDAC Endpoints tumors CRC Primary: • Previously treated with o
Slide 38: DS-6000 Progress in FY2023
DS-6000 (R-DXd) Progress in FY2023 Promising data were obtained in platinum resistant ovarian cancer and new Ph2/3 study started Efficacy in Ph1 study (SGO 2024) Data Cutoff: July 2023 ◼ DS-6000 demonstrated strong clinical activity and manageable safety profile in Ph1 study platinum resistant ovari
Slide 39: Hematological malignancy Progress in FY2023
Hematological malignancy Progress in FY2023 Providing new treatment options addressing high unmet medical needs VANFLYTA ® ◼ Approved in countries and regions shown below based on QuANTUM-First study (Ph3) for FLT3-ITD positive AML 1L ◼ May 2023: Japan ◼ Jul 2023: US ◼ Nov 2023: EU Valemetostat (Bra
Slide 40: Next Wave Other Progress in FY2023
Next Wave Other Progress in FY2023 Oncology Vaccine ◆ DS-3939 (TA-MUC1 directed ADC) ◆ DAICHIRONA® FOR INTRAMUSCULAR INJECTION* ➢ Ph1/2 study for solid tumors started in Sep 2023 (COVID-19 vaccine) ➢ Vaccine for original strain was approved in Japan in Aug 2023 ◆ DS-1471 (anti-CD147 antibody) ➢ Vacc
Slide 41: ASCO 2024 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2024 News Flow 41
Slide 42: ASCO Highlight 2024: IR conference call
ASCO Highlight 2024: IR conference call Hiroyuki Okuzawa Ken Takeshita Mark Rutstein President and COO Head of Global R&D Head of Global Oncology Development Jun 4, 2024 (Tue) 8:00-9:00am JST/ Date and Time Jun 3, 2024 (Mon) 6:00-7:00pm CDT Meeting style Virtual (Zoom) Content will be delivered on-d
Slide 43: ASCO 2024 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2024 News Flow 43
Slide 44: FY2024 News Flow
FY2024 News Flow As of Apr 2024 Planned major publications Regulator y decisions American Society of Clinical Oncology（ASCO, May 31-Jun 4, 2024） HERTHENA-Lung01: EGFR mutated NSCLC, 3L HER3-DXd • US: FY2024 H1 DESTINY-Breast03: HER2+ BC, 2L, Ph3 • Updated OS data VALENTINE-PTCL01：r/r PTCL DESTINY-Br
Slide 45: Agenda: 5-Year Business Plan Update
Agenda 1 FY2023 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2024 Forecast 6 Appendix 45
Slide 46: Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025)
Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025) Realize 2025 Goal and Shift to Further Growth FY2025 ◆ Revenue: 1.6 Tr JPY (Oncology > 600.0 Bn JPY) ◆ ROE > 16% Financial Targets ◆ Core Operating Profit* Ratio before R&D Expense: 40％ ◆ DOE** > 8% Profit growth for current Identify and
Slide 47: 5-Year Business Plan: Progress in FY2021-FY2023
5-Year Business Plan: Progress in FY2021-FY2023 Maximize 3ADCs Profit growth for current business and products ◆ Maximize product value of ENHERTU® ◆ Growth of current products ➢ Approval of new indication ➢ Steady sales expansion of Lixiana® • HER2+ BC 2L, HER2 low BC post-chemo, • Increase product
Slide 48: 5-Year Business Plan: Progress in FY2021-FY2023
5-Year Business Plan: Progress in FY2021-FY2023 Identify and build pillars for further growth Create shared value with stakeholders ◆ Emerging growth drivers following 3ADCs ◆ Strengthening shareholder returns ➢ Progress of development for I-DXd (B7-H3-direceted ➢ Increase dividend taking account of
Slide 49: Estimate for FY2025 KPIs
Estimate for FY2025 KPIs (as of Apr. 2024) 5YBP Target Estimate Estimate (Apr. 2021) as of Apr. 2023 as of Apr. 2024 Revenue 1,600 Bn JPY 2.0 Tr JPY 2.1 Tr JPY Revenue in Oncology > 600 Bn JPY > 900 Bn JPY > 1.0 Tr JPY Core Operating Profit ratio before R&D expense 40% 40% 40% ROE > 16% > 16% > 16%
Slide 50: Estimated Oncology Revenue
Estimated Oncology Revenue (as of Apr. 2024) Estimate oncology revenue of 1 Tr JPY or more in FY2025 driven by further revenue growth of ENHERTU® and upfront payments related to strategic collaboration with MRK*1 for HER3-DXd, I-DXd, and DS-6000 Increase/decrease from Apr. 2023 estimation Image for
Slide 51: Estimated R&D Expenses
Estimated R&D Expenses (as of Apr. 2024) Estimate R&D expenses of approx. 1 Tr JPY for FY2024 and FY2025 in total driven by new study initiation for ENHERTU® and other expenses Increase/decrease from Apr. 2023 estimation R&D expenses trend Major Increase ◆ Initiation of new studies for ENHERTU® *1 a
Slide 52: Well-balanced Investment for Growth and Shareholder Returns
Well-balanced Investment for Growth and Shareholder Returns Cash Allocation Increase R&D expense and CAPEX for further growth in future, and increase shareholder returns with cash flow of approx. 600.0 Bn JPY increased due to the received upfront payment related to strategic collaboration with MRK e
Slide 53: Forecast of FY2025 KPIs
Forecast of FY2025 KPIs (as of Apr. 2024) ◆Revenue Achieve significant revenue/profit growth 2.1 Tr JPY after investment for DXd ADCs, and shift to a new stage for realizing 2030 vision ➢Revenue in Oncology > 1 Tr JPY 1,740.0 Bn JPY 1,601.7 Bn JPY Revenue 1,278.5 Bn JPY 1,049.9 680.0 Bn JPY 559.6 Bn
Slide 54: Daiichi Sankyo will contribute to the enrichment of quality of life around the world
Daiichi Sankyo will contribute to the enrichment of quality of life around the world 54
Slide 55: Agenda: FY2024 Forecast
Agenda 1 FY2023 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2024 Forecast 6 Appendix 55
Slide 56: FY2024 Forecast
FY2024 Forecast (Bn JPY) Revenue Increase factor Sales expansion of main products (Enhertu, Lixiana, Tarlige, etc.) FY2023 FY2024 vs. Forecast Deferred revenue increase from upfront payments related to Results Forecast strategic collaboration with Merck Revenue 1,601.7 1,750.0 +148.3 Decrease Factor
Slide 57: FY2024 Annual Dividend Forecast
FY2024 Annual Dividend Forecast Increase annual dividend per share from 50 JPY (FY2023) to 60 JPY (FY2024) taking account of increasing probability of achieving FY2025 KPIs following further sales expansion of EnhertuⓇ Annual dividend per share in FY2024: 60 JPY (interim dividend: 30 JPY, year-end d
Slide 58: Flexible Acquisition of Own Shares
Flexible Acquisition of Own Shares ◆ Decided acquisition and cancellation of own shares for shareholder returns enhancement and capital efficiency improvement ◆ FY2025 DOE is expected over 8.5% which exceeds the original target ➢ Acquisition period: Apr. 26, 2024 – Jan. 15, 2025 Acquisition ➢ Aggreg
Slide 59: Agenda: Appendix
Agenda 1 FY2023 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2024 Forecast 6 Appendix 59
Slide 60: 3ADCs launch plan
3ADCs launch plan Realize maximizing the product values of 3ADCs through expanding the indications FY2026 & Beyond 5-Year Business Plan (FY2021-FY2025) ENHERTUⓇ ENHERTUⓇ Dato-DXd DESTINY-Breast05 DESTINY-Breast03 TROPION-Lung01 DESTINY-Gastric04 ~FY2020 • Combo with DS internal asset, I/O or DESTINY
Slide 61: Major R&D Milestones (ENHERTU)
Major R&D Milestones (ENHERTU®) As of Apr 2024 FY2023 FY2024 Project Target indication [phase, study name] H2 H1 H2 • HR+/HER2 low, chemo naive • TLR anticipated [Ph3, DESTINY-Breast06] BC • HER2+, neoadjuvant • TLR anticipated [Ph3, DESTINY-Breast11] • HER2+, 3L+ • Regulatory decision GC • Filing a
Slide 62: Major R&D Milestones (Dato-DXd)
Major R&D Milestones (Dato-DXd) As of Apr 2024 FY2023 FY2024 Project Target indication [phase, study name] H2 H1 H2 • Regulatory decision • 2/3L [Ph3, TROPION-Lung01] • Filing accepted (US, EU) anticipated (US) • 1L, nonsquamous, PD-L1 high, rilvegostomig • Study start NSCLC combo planned [TROPION-L
Slide 63: Major R&D Milestones (HER3-DXd, I-DXd, DS-6000)
Major R&D Milestones (HER3-DXd, I-DXd, DS-6000) As of Apr 2024 FY2023 FY2024 Project Target indication [phase, study name] H2 H1 H2 • EGFR mutant, 3L • Regulatory decision • Filing accepted (US) [Ph2, HERTHENA-Lung01] anticipated (US) NSCLC • EGFR mutant, 2L • TLR anticipated HER3-DXd [Ph3, HERTHENA
Slide 64: Major R&D Milestones (Next Wave)
Major R&D Milestones (Next Wave) As of Apr 2024 FY2023 FY2024 Project Target indication [phase, study name] H2 H1 H2 • Regulatory • r/r PTCL [Registrational Ph2, VALENTINE-PTCL01] • Filing accepted (JP) decision anticipated (JP) valemetostat • HER2+ GC, non-squamous NSCLC • Study started [Ph1b、ENHER
Slide 65: Major R&D Pipeline: 5DXd ADCs
Major R&D Pipeline: 5DXd ADCs As of Apr 2024 Phase 1 Phase 2 Phase 3 Regulatory phase (US/EU/Asia) HER2+ BC 2L+/1L (JP/US/EU/Asia) NSCLC (w/o AGA, (CN) HER2 expressing solid tumors (JP/US/EU/Asia) HER2+ BC (JP/US/EU/Asia) in prep PD-L1 high (CN) HER2+ GC 3L DESTINY-Breast07 pembrolizumab combo) DEST
Slide 66: Major R&D Pipeline: Next Wave
Major R&D Pipeline: Next Wave As of Apr 2024 Phase 1 Phase 2 Phase 3 Regulatory phase DS-1055 (JP/US) DS-7011 (US) Valemetostat (EU) Pexidartinib (JP/Asia) Valemetostat (JP) Anti-GARP antibody Anti-TLR7 antibody EZH1/2 inhibitor CSF-1/KIT/FLT3 inhibitor EZH1/2 inhibitor Solid tumors Systemic lupus e
Slide 67: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: DaiichiSankyoIR@daiichisankyo.co.jp 67
Daiichi Sankyo Co Ltd Ord — FY2023 Earnings Presentation on 6ix